Other
CN
EU
USA
Description: Olanzapine (formerly LY-170052, LY 170052, Zyprexa, Zolafren), a thienobenzodiazepine analog, is an approved atypical antipsychotic drug with high affinity for 5-HT2 serotonin and D2 dopamine receptor. It acts as a 5-HT2 serotonin and dopamine antagonist. Binding studies showed that olanzapine interacted with keyreceptorsof interest in schizophrenia, exihibiting a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscarinic receptors. It is approved by the U.S. FDA for the treatment of schizophrenia and bipolar disorder. Olanzapine is structurally similar to clozapine and quetiapine.
References: J Clin Psychiatry. 1997;58 Suppl 10:28-36; Neuropsychopharmacology. 2000 Sep;23(3):250-62.
Related CAS#: 174794-02-6 (Olanzapine N-Oxide)
Product Catalog 2022
Guide to Product Handling
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity: Olanzapine interacts with key receptors of interest in schizophrenia, having a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscarinic receptors. Olanzapine has a receptor profile that is similar to that of clozapine: it is relatively nonselective at dopamine receptor subtypes and it shows selectivity for mesolimbic and mesocortical over striatal dopamine tracts (electrophysiology; Fos).
Purity ≥98%
COA
MSDS
NMR